Year: 2011
Type: article
Abstract: In this issue of Haematologica, Itzykson et al. for the ALFA group show that the choice of post-remission therapy has seemingly little effect on duration of survival after complete remission in patients aged 65–70 years old with acute myeloid leukemia (AML).[1][1] In more detail, survival times
Source: Haematologica
Author: E. H. Estey
Institution: Fred Hutch Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W2096815971